Tyck till om SwePub Sök
här!
Sökning: onr:"swepub:oai:DiVA.org:uu-121105" >
Lipoprotein lipase ...
Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity
-
- Mansouri, Mahmoud (författare)
- Karolinska Institutet,Uppsala universitet,Institutionen för genetik och patologi,Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
-
- Sevov, Marie (författare)
- Uppsala universitet,Medicinsk genetik och genomik,Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
-
- Fahlgren, Emma (författare)
- Umeå universitet,Fysiologisk kemi
-
visa fler...
-
- Tobin, Gerard (författare)
- Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
-
- Jondal, Mikael (författare)
- Department of Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
-
- Osorio, Lyda (författare)
- Karolinska Institutet
-
- Roos, Göran (författare)
- Umeå universitet,Patologi
-
- Olivecrona, Gunilla (författare)
- Umeå universitet,Fysiologisk kemi
-
- Rosenquist, Richard (författare)
- Uppsala universitet,Institutionen för genetik och patologi,Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2010
- 2010
- Engelska.
-
Ingår i: Leukemia research. - : Elsevier BV. - 0145-2126 .- 1873-5835. ; 34:3, s. 301-306
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Lipoprotein lipase (LPL) expression has been shown to correlate with IGHV mutational status and to predict outcome in chronic lymphocytic leukemia (CLL). We here investigated the prognostic impact of LPL expression in relation to other prognostic markers including IGHV3-21 usage in 140 CLL patients. Additionally, we studied the catalytic activity of LPL in CLL cells. A significant difference in LPL mRNA expression was detected in IGHV unmutated compared to mutated CLL patients (p<0.001). However, the poor-prognostic mutated/stereotyped IGHV3-21 patients did not differ from other mutated CLL cases. Clinical outcome was significantly different in CLL cases with high versus low LPL expression (p<0.001), and LPL expression exceeded mutation status/IGHV3-21 usage as an independent prognostic marker. Finally, LPL protein expression correlated significantly with mRNA expression and was higher in IGHV unmutated versus mutated CLL (p=0.018), although the majority of synthesized protein was catalytically inactive indicating a non-catalytical function in CLL.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- LPL expression
- LPL catalytical activity
- IGHV mutational status
- IGHV3 21 usage
- Chronic lymphocytic leukemia
- Prognosis
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas